**Evaluating safety reporting in paediatric antibiotic trials 2000-2016: a systematic review and meta-analysis**

**Subheading: Safety reporting in paediatric antibiotic clinical trial 2000-2016**

***Drugs***

**1,2Paola Pansa, MD; 1Yingfen Hsia, PhD; 1,3Julia Bielicki, MD; 4Irja Lutsar, MD; 5A. Sarah Walker, PhD; 1Mike Sharland, MD; 1\*Laura Folgori, MD**

1 Paediatric Infectious Disease Research Group, Institute for Infection and Immunity, St George's University of London, Cranmer Terrace, London SW17 0RE, UK

2 Department of Pediatrics, Sapienza University of Rome, Policlinico Umberto I, Viale Regina Elena 324, 00161 Rome, Italy

3 Paediatric Pharmacology, University Children’s Hospital Basel, Spitalstrasse 33 4056, Basel, Switzerland

4 Institute of Medical Microbiology, University of Tartu, Ravila 19, 50411 Tartu, Estonia

5 Nuffield Department of Clinical Medicine; NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford OX1 3PA, UK

**\*Corresponding author:** Laura Folgori

Mailing address: St George's University of London, Jenner Wing, Level 2, Room 2.215E, Cranmer Terrace, London, SW17 0RE, United Kingdom

E-mail address: lfolgori@sgul.ac.uk

Telephone number: +44 20 87254851

**eFig. 1** Toxicity in Aminoglycosides: one daily dose (OD) versus multiple daily doses (MD) Meta-analysis (A: nephrotoxicity, B: ototoxicity)



**eFig. 2** Macrolides vs Penicillins (overall AEs): Meta-analysis



**eFig. 3** Funnel plot of: A-B-C: diarrhoea in β-lactams (A: penicillins vs other beta-lactams; B: penicillins+beta lactamase inhibitor vs other beta-lactams; C: Cephalosporins vs other beta-lactams); D-E: Toxicity in one daily vs multiple doses of aminoglycosides (D: Nephrotoxicity; E: Ototoxicity); F: overall AEs in macrolides vs penicillins

